Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 401-990-0 | CAS number: 106990-43-6 CHIMASSORB 119; LOWILITE 19
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 01-21-1999 to 03-29-1999
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 999
- Report date:
- 1999
Materials and methods
- Objective of study:
- distribution
- excretion
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 417 (Toxicokinetics)
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- NOTOX B.V., The Netherlands
Test material
- Reference substance name:
- N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino)triazin-2-yl)-4,7-diazadecane-1,10-diamine
- EC Number:
- 401-990-0
- EC Name:
- N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino)triazin-2-yl)-4,7-diazadecane-1,10-diamine
- Cas Number:
- 106990-43-6
- Molecular formula:
- C132 H250 N32
- IUPAC Name:
- N2-[2-({4,6-bis[butyl(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]-1,3,5-triazin-2-yl}[3-({4,6-bis[butyl(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]-1,3,5-triazin-2-yl}amino)propyl]amino)ethyl]-N2-[3-({4,6-bis[butyl(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]-1,3,5-triazin-2-yl}amino)propyl]-N4,N6-dibutyl-N4,N6-bis(1,2,2,6,6-pentamethylpiperidin-4-yl)-1,3,5-triazine-2,4,6-triamine
- Details on test material:
- - Physical state: white solid
- Radiochemical purity (if radiolabelling): 98 %
- Specific activity (if radiolabelling): 3.92 GBq/mmol (by mass spectrometry), 1.79 MBq/mg (by gravimetric analysis)
- Stability under test conditions: stable
- Storage condition of test material: room temperature in dark for Non-radiolabelled and in freezer in the dark for radiolabelled test material.
Constituent 1
- Radiolabelling:
- yes
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, Sulzfeld, Germany.
- Age at study initiation: 7 weeks old
- Weight at study initiation: ranged between 270 and 292 g.
- Fasting period before study: 18 hours
- Housing: individually housed in Macrolon plastic cages
- Individual metabolism cages: yes
- Diet (e.g. ad libitum): standard pelleted laboratory animal diet (Carfil Quality BVBA, Oud-Tumhout, Belgium)
- Water (e.g. ad libitum): tap water
- Acclimation period: 8 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18-25
- Humidity (%): 40-80
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12
IN-LIFE DATES: From: January 21, 1999 To: April 14, 1999
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
The formulations were prepared immediately prior to dosing. The required amount of [14C]-test article was weighed into an empty glass container. After addition of the required amount of non-radiolabelled test material, a weighed amount of the vehicle was added to achieve the final concentration. For groups 1M and 2M (50 and 1000 mg/kg bw respectively), the nominal test material concentration was 10 and 200 mg/ml, with a nominal radioactivity concentration of 2.4 MBq/ml. The formulations were stored at ambient temperature on a magnetic stirring device for a maximum of 4 hours.
VEHICLE
- Amount of vehicle (if gavage): Dose volume of 5 mL/kg bw, the nominal radioactivity contained in each dose was approximately 3 MBq.
HOMOGENEITY AND STABILITY OF TEST MATERIAL:
Immediately after preparation and prior to dose administration, the homogeneity and radioactivity concentration of each formulation were verified by radioanalysis. - Duration and frequency of treatment / exposure:
- Single dose
Doses / concentrationsopen allclose all
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose / concentration:
- 4
- Control animals:
- no
- Details on dosing and sampling:
- PHARMACOKINETIC STUDY (distribution, excretion)
- Tissues and body fluids sampled :
1) Urine samples were collected from all animals over the following time intervals: 0-24, 24-48, 48-72, and 72- 96 hours after administration of [14C]-labeled test substance. The urine was freeze-trapped to avoid atmospheric oxidation, evaporation and bacterial degradation. Faeces were collected on dry ice over the same time intervals as urine. All urine and faeces samples were stored at < -20°C until analysis. At termination the interior of the cages was rinsed with methanol/water (50/50). The cage rinse was weighed and stored at < - 20° until analysis.
2) Volatiles: For all animals, expired CO2 was collected in a 2N NaOH solution, and other volatiles in cellosolve, over the following nominal time intervals: 0-8, 8-24, 24-36, and 36-48 h after the administration of [14C]-test material. Sample weight was determined at the end of each collection period. Samples were refrigerated at approximately 4°C for a maximum of 3 days, within which period the analyses were completed. Following completion of the analysis, the remainder of the study sample was discarded.
3) All animals were anaesthetised using ether at 96 h after administration of [14C]-test article. The thorax and abdomen were opened with a midline incision. By means of aorta punction the maximum possible amount of blood was withdrawn. Care was taken to avoid contamination of other organs with blood. Sampled blood was transferred into preweighed heparinised tubes. A subsample of approximately 1 mL of the heparinised blood was removed for total C analysis. The remaining blood was centrifuged to obtain the plasma which was weighed and stored at < -20°C until analysis. Following the removal of the blood, the following tissues and organs were harvested: liver, kidneys, spleen, abdominal fat, muscle (left hind leg), G.I. tract, lymph nodes (mesenteric lymph nodes and Peyer's patches), gonads (testes, seminal vesicles, and prostate), bone (left femur), thymus, skin, brain and carcass. The weight of each tissue and blood sample was recorded at the time it was harvested. All biological samples were stored at < -20°C until analysis.
Radioactivity measurements:
All samples were subjected to radioactive measurements performed using a Packard scintillation counter (1900TR) with automatic external standard quench correction. - Statistics:
- The mean and standard deviation were used to characterise the data, where appropriate (i.e., radioactivity measurement, concentration, etc.). Concentrations of radioactivity in blood, plasma and tissues were calculated as mg equivalents of [14C]-test material /kg of sample. The total amounts of radioactivity in tissue and excreta samples were calculated as a percentage of the administered radioactivity and a 14C mass balance was presented.
Results and discussion
Toxicokinetic / pharmacokinetic studies
- Details on distribution in tissues:
- - Concentrations of radioactivity in blood, plasma and tissues: For group 1M, the highest mean tissue concentrations were recorded in the spleen and the mesenteric lymph nodes (0.99 and 1.04 mg/kg tissue, respectively). Similar mean tissue levels were recorded in the thymus, G.I tract, Peyer's patches, skin, bone, liver and kidney (0.11-0.55 mg/kg). In the remaining tissues and organs analysed (brain, blood, testes, prostate, seminal vesicles, abdominal fat and femoral muscle), mean radioactivity concentrations were about an order of magnitude lower (0.012-0.063 mg/kg). For group 2M, the highest mean tissue concentrations were recorded in the spleen and the G.I. tract (26.9 and 18.0 mg/kg, respectively). The mean tissue concentrations in thymus, Peyer's patches, skin, bone, liver and kidney of the animals of group 2M was 3.86-11.2 mg/kg. In the remaining tissues and organs analysed (brain, mesenteric lymph nodes, blood, testes, prostate, seminal vesicles, abdominal fat and femoral muscle), mean radioactivity concentrations were about an order of magnitude lower (0.11-1.96 mg/kg). The mean concentration in the plasma (0.002 mg/kg for group 1M and <0.16 mg/kg for group 2M) was a factor of at least 12 lower than in the blood (0.056 mg/kg for group 1M and 1.94 mg/kg for group 2M).
- Amounts of radioactivity (percent of dose) in blood, plasma and tissues: The mean amount of radioactivity was highest in the G.I tract (0.14-0.22%), followed by liver (0.057-0.059 %). In all other tissues and organs analysed, the mean amount of radioactivity was <0.007% of the dose. The carcass of the animals of group 1M and 2M contained a mean 1.27 and 0.84% of the dose. The total mean amount of radioactivity recovered from tissues and carcass at 96 h post dose was 1.49 and 1.14% for groups 1M and 2M, respectively.
- Details on excretion:
- - Volatiles: The amount of expired volatile radioactivity was minimal and the sampling was discontinued after 48 h. For group 1M and 2M, mean recoveries of radioactivity in the CO2 traps were 0.007 and 0.003%, respectively. The amount of expired organic volatiles was <0.001% in anyone sample analysed.
- Faeces: The majority of the radioactive dose was excreted in the faeces, mostly during the first 24 hours post dose (group 1M) or during the first 48 hours post dose (group 2M). Mean total recoveries from the faeces during the 96-h test period were 82 and 97% for groups IM and 2M, respectively (at a mean mass balance of 85 and 98%, respectively) (Table 1).
- Urine: Mean total recoveries from the urine during the 96-h test period were 0.60 and 0.28% for groups 1M and 2M, respectively (Table 1).
Metabolite characterisation studies
- Metabolites identified:
- not measured
Any other information on results incl. tables
- Each animal received a radioactive dose of [14C]-test material which ranged between 2.9 and 3.0 MBq. The animals of group 1M (nominal dose 50 mg/kg bw) received an actual dose of test material which ranged between 48 and 54 mg/kg bw corresponding with 96 and 108% of the nominal dose respectively. The animals of group 2M (nominal dose 1000 mg/kg bw) received an actual dose of test material which ranged between 1018 and 1065 mg/kg bw corresponding with 102 and 107% of the nominal dose respectively. The administered doses were considered to be sufficiently close to the target levels in order to fulfill the study's objectives.
- No mortalities occurred during the study. On day 3 of the study, animal 5 of group 2 was observed to have a scab near the tail tip. There were no other antemortem observations. During tissue harvest no abnormalities were noted.
Table: Amount (mean ± SD) of total radioactivity found in faeces and urine from male rats dosed with [14C-] test article/kg bw.
Interval (h) |
% of dose in faeces |
% of dose in urine |
||
50 mg/kg bw |
1000 mg/kg bw |
50 mg/kg bw |
1000 mg/kg bw |
|
0-24 |
71.7±18.6 |
43.9±12.4 |
0.25±0.38 |
0.05±0.06 |
24-48 |
7.69±5.51 |
44.8±10.6 |
0.20±0.17 |
0.14±0.15 |
48-72 |
2.31±2.85 |
6.6±7.55 |
0.09±0.08 |
0.06±0.11 |
72-96 |
0.64±0.48 |
1.24±1.55 |
0.06±0.06 |
0.03±0.05 |
Total |
82.3±12.0 |
96.6±4.46 |
0.60±0.67 |
0.28±0.35 |
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.